ERX-315-001 SITE INITIATION VISIT @TKCC
Sydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney Australia for the ERX-315-001 Phase 1 clinical trial. The study related protocol, procedures, processes, monitoring plan and study logistics ranging from patient selection to drug compounding to patient monitoring after administration were reviewed with the clinical trials team at TKCC.
The clinical trial titled “A Phase 1 Trial of ERX-315 in Participants with Advanced Solid Tumors” was approved by the Australian regulatory authorities in August. The trial will evaluate the safety and tolerability of ERX-315 in in patients with advanced solid tumors, who have progressed on prior approved systemic therapies. Interested individuals can learn more about the trial, eligibility criteria, and how to participate by visiting the link here: ERX-315 Clinical Trial.
The Site Initiation Visit confirms TKCC’s readiness to conduct the trial. Following final approvals by TKCC, the recruitment to the trial at the TKCC will commence later this month and will be overseen by the overall trial principal investigator, Dr. Rasha Cosman, the Head of Early Phase Clinical Trials Unit and the Clinical Lead of Oncology Clinical Trials at TKCC.
TKCC is a major Australian cancer center focusing on translational research and personalised cancer care with a mission to align world-class cancer research with rapid translation to the clinic. TKCC is located in Darlinghurst suburb of Sydney and affliated with St Vincent’s Hospital Sydney, a world-class public hospital.
Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase. Novotech has worked closely with Etira in advancing ERX-315 to clinical trials.
Etira will provide updates on the continued progress of the ERX-315 clinical trial and activation in additional clinical trial sites in Australia. This clinical trial represents a significant step forward in Etira’s pursuit of effective treatments for patients with metastatic therapy-resistant cancers.
